Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer

Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00193349

Enrollment

Registered

2005-09-19

Start date

2002-09-30

Completion date

2007-12-31

Last updated

2010-06-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

This study will evaluate combination chemotherapy for patients with extensive stage small cell lung cancer combined with the potentially useful growth inhibiting effects of Gleevec.

Detailed description

Upon determination of eligibility, all patients will be receive: * Irinotecan + Carboplatin + Imatinib

Interventions

DRUGImatinib

DRUGIrinotecan

DRUGCarboplatin

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

To be included in this study, you must meet the following criteria: * Small cell lung cancer with extensive stage disease confirmed by biopsy * Measurable or evaluable disease * Ability to perform activities of daily living with minimal assistance * Adequate bone marrow, liver and kidney * No active brain metastasis. * No previous chemotherapy or radiation therapy * Give written informed consent.

Exclusion criteria

You cannot participate in this study if any of the following apply to you: * Limited stage disease (includes IA, IB, IIA, IIB, and IIIA) * Active brain metastasis * Age \< 18 years old * History of a prior malignancy within three years * Women pregnant or lactating. Please note: There are additional inclusion/

Design outcomes

Primary

Measure	Time frame
Overall response rate	—
Response duration	—

Secondary

Measure	Time frame
Time to progression	—
Overall toxicity	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026